Viskase Holdings, INC. (ENZN) — 8-K Filings

8-K Filings (14)

• Viskase Holdings Reports Asset Deal, Equity Sales, Control Changes — Mar 26, 2026 Risk: medium
  Viskase Holdings, Inc. filed an 8-K on March 26, 2026, reporting the completion of an acquisition or disposition of assets. The filing also disclosed unregister
• ENZON PHARMACEUTICALS Files 8-K: Regulation FD Disclosure — Mar 25, 2026
  ENZON PHARMACEUTICALS, INC. filed an 8-K on March 25, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This f
• 8-K Filing — Dec 23, 2025
• Enzon Pharmaceuticals Files 8-K for Material Agreement — Oct 24, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. filed an 8-K on October 24, 2025, reporting a material definitive agreement. The filing also includes Regulation FD disclosures and
• Enzon Pharmaceuticals Files 8-K: Material Agreement & Security Holder Updates — Sep 30, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. filed an 8-K on September 30, 2025, reporting an entry into a material definitive agreement and modifications to the rights of secur
• Enzon Pharmaceuticals Files 8-K: Material Agreement — Jun 23, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. entered into a Material Definitive Agreement on June 20, 2025. The filing also includes Regulation FD Disclosure and Financial State
• Enzon Pharmaceuticals Files 8-K: Material Agreement & More — Apr 1, 2025 Risk: medium
  On March 31, 2025, Enzon Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also addresses modifications to securit
• Enzon Pharmaceuticals CFO Departs, New CFO Appointed — Jan 10, 2025 Risk: medium
  Enzon Pharmaceuticals, Inc. announced on January 7, 2025, the departure of its Chief Financial Officer, David J. Stack, effective January 10, 2025. The company
• Amneal Pharmaceuticals to Acquire Enzon Pharmaceuticals — Dec 27, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. announced on December 18, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuti
• Enzon Pharmaceuticals 8-K: Shareholder Vote Update — Oct 1, 2024 Risk: low
  Enzon Pharmaceuticals, Inc. filed an 8-K on October 1, 2024, reporting on matters submitted to a vote of security holders on September 26, 2024. The filing deta
• Enzon Pharmaceuticals Files 8-K on Shareholder Nominations — Jul 2, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. filed an 8-K on July 2, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing details the comp
• Amneal Pharmaceuticals to Acquire Enzon Pharmaceuticals — Jun 14, 2024 Risk: medium
  Enzon Pharmaceuticals, Inc. announced on June 10, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Amneal Pharmaceuticals
• Enzon Pharmaceuticals Enters Material Definitive Agreement — May 22, 2024 Risk: medium
  On May 16, 2024, Enzon Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing also notes material modifications to the rights of securit
• ENZON PHARMACEUTICALS Files Administrative 8-K on Dec 31 Event — Jan 5, 2024
  ENZON PHARMACEUTICALS, INC. filed an 8-K on January 5, 2024, reporting an 'Other Event' that occurred on December 31, 2023. The filing indicates the company is

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX